Effect of Sanguisorba officinalis L on breast cancer growth and angiogenesis

Expert Opinion on Therapeutic Targets

Volumn 16, Issue SUPPL. 1, 2012, Pages

  Wang, Zhiyu ^a   Loo, Wings Ty ^a,b   Wang, Neng ^a   Chow, Louis Wc ^b   Wang, Dongmei ^c   Han, Feng ^d   Zheng, Xiao ^a   Chen, Jian Ping ^a,c  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIMED Medical Institute   (Hong Kong)

^c SUN YAT SEN UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Angiogenesis; Apoptosis; Breast cancer; Sanguisorba officinalis L

Indexed keywords

ANTINEOPLASTIC AGENT; PLANT EXTRACT; SANGUISORBA OFFICINALIS EXTRACT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; ELLAGIC ACID; FEMALE; GALLIC ACID; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PHYTOTHERAPY; PLANT EXTRACTS; SANGUISORBA;

EID: 84863260112     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.642371     Document Type: Article

References (26)

1. Patani N, Mokbel K. Herceptin and breast cancer: an overview for surgeons. Surg Oncol 2010;19:e11-21
2. Yamashiro H, Toi M. Molecular targeted therapy for breast cancer treatment, challenge to cure. Nippon Rinsho 2010;68:1854-8
3. Zhukov NV, Tjulandin SA. Targeted therapy in the treatment of solid tumors: practice contradicts theory. Biochemistry (Mosc) 2008;73:605-18 (Pubitemid 351775082)
4. Desai AG, Qazi GN, Ganju RK, et al. Medicinal plants and cancer chemoprevention. Curr Drug Metab 2008;9:581-91
5. Efferth T. Cancer therapy with natural products and medicinal plants. Planta Med 2010;76:1035-6
6. Efferth T, Li PC, Konkimalla VS, Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 2007;13:353-61 (Pubitemid 47126989)
7. Zhu M, Wong PY, Li RC. Influence of Sanguisorba officinalis, a mineral-rich plant drug, on the pharmacokinetics of ciprofloxacin in the rat. J Antimicrob Chemother 1999;44:125-8 (Pubitemid 29353693)
8. Jiang L, Liao HX, Jin HH, Wang W. Clinical Observation of diyushengbai tablet and G-CSF on cure arrest of bone marrow after chemotherapy of gynaecology tumour. Chin J Basic Med Tradit Chin Med 2010;16:1079-80
9. Lee NH, Lee MY, Lee JA, et al. Anti-asthmatic effect of Sanguisorba officinalis L. and potential role of heme oxygenase-1 in an ovalbumin-induced murine asthma model. Int J Mol Med 2010;26:201-8
10. Kim TG, Kang SY, Jung KK, et al. Antiviral activities of extracts isolated from Terminalis chebula Retz., Sanguisorba officinalis L., Rubus coreanus Miq. and Rheum palmatum L. against hepatitis B virus. Phytother Res 2001;15:718-20 (Pubitemid 34016802)
11. Liu X, Cui Y, Yu Q, Yu B. Triterpenoids from Sanguisorba officinalis. Phytochemistry 2005;66:1671-9 (Pubitemid 41026620)
12. Bastow KF, Bori ID, Fukushima Y, et al. Inhibition of DNA topoisomerases by sanguiin H-6, a cytotoxic dimeric ellagitannin from Sanguisorba officinalis. Planta Med 1993;59:240-5 (Pubitemid 23168771)
13. Wang ZY, Wang DM, Loo TY, et al. Spatholobus suberectus inhibits cancer cell growth by inducing apoptosis and arresting cell cycle at G2/M checkpoint. J Ethnopharmacol 2011;133:751-8
14. Efferth T. Personalized cancer medicine: from molecular diagnostics to targeted therapy with natural products. Planta Med 2010;76:1143-54
15. Youns M, Hoheisel JD, Efferth T. Traditional Chinese medicines (TCMs) for molecular targeted therapies of tumours. Curr Drug Discov Technol 2010;7:37-45
16. Chen HM, Wu YC, Chia YC, et al. Gallic acid, a major component of Toona sinensis leaf extracts, contains a ROS-mediated anti-cancer activity in human prostate cancer cells. Cancer Lett 2009;286:161-71
17. Edderkaoui M, Odinokova L, Ohno I, et al. Ellagic acid induces apoptosis through inhibition of nuclear factor kappaB in pancreatic cancer cells. World J Gastroenterol 2008;14:3672-80
18. Cerda B, Tomas-Barberan FA, Espin JC. Metabolism of antioxidant and chemopreventive ellagitannins from strawberries, raspberries, walnuts, and oak-aged wine in humans: identification of biomarkers and individual variability. J Agric Food Chem 2005;53:227-35 (Pubitemid 40129908)
19. Giftson JS, Jayanthi S, Nalini N. Chemopreventive efficacy of gallic acid, an antioxidant and anticarcinogenic polyphenol, against 1,2-dimethyl hydrazine induced rat colon carcinogenesis. Invest New Drugs 2010;28:251-9
20. Khanduja KL, Gandhi RK, Pathania V, Syal N. Prevention of N-nitrosodiethyla mine-induced lung tumorigenesis by ellagic acid and quercetin in mice. Food Chem Toxicol 1999;37:313-18 (Pubitemid 29335758)
21. Kang JX, Liu J, Wang J, et al. The extract of huanglian, a medicinal herb, induces cell growth arrest and apoptosis by upregulation of interferon-beta and TNF-alpha in human breast cancer cells. Carcinogenesis 2005;26:1934-9 (Pubitemid 41631267)
22. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210-21
23. Pirker R. Bevacizumab in lung cancer: hurdles in clinical development. Lancet Oncol 2010;11:703-4
24. Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial gorwth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009;10:967-74
25. Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010;60:222-43
26. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6:507-18